Stress hyperglycemia is associated with worse outcomes, but its associated risks and contributors are not well known. We evaluated characteristics associated with high inpatient random plasma glucose levels (RPG) in a retrospective cohort of the national VA Health Care System. Patients were age ≥18 yrs, without diagnosed diabetes (DM), hospitalized ≥3 days in 2002-2014 with ≥2 RPGs, and had regular care ≥2 yrs before and ≥3 yrs after hospitalization. In 205,270 pts, mean age was 73.8 yrs and BMI 28.0 kg/m2; 96% were male, 75% white, 16% black. Second highest inpatient RPG levels (iRPG-2max) of <130, 130-139, 140-159, 160-179, 180-199, and ≥200 mg/dl were found in 63%, 10%, 13%, 6%, 3%, and 4% of patients, respectively, without demographic differences between groups. Those with higher iRPG-2max had longer lengths of stay (LOS; median 5 days with <130 mg/dl vs. 10 days with ≥200, p<0.001), and higher rates of acute kidney injury (AKI; 9.3% with <130 vs. 29.3% with ≥200 group; OR 3.8, 95% CI 3.6-4.0) but no differences in rates of infection. Before admission, higher iRPG-2max groups were more likely to have ≥2 outpatient RPGs (oRPG) ≥130 mg/dl (7.2% with <130 mg/dl vs. 15.2% with ≥200, p<0.001). After discharge, higher iRPG-2max groups had more incident DM within 1 and 3 yrs (1.3% and 3.4%, respectively, with <130 vs. 14.9% and 18.4% with ≥200, both p<0.001). In multivariate analysis, higher iRPG-2max was more likely with oRPG ≥130 mg/dl vs. oRPG <110 (adj OR 1.81, 95% CI 1.75-1.87), and with DM in 3 yrs post-discharge vs. no DM (adj OR 2.52, 95% CI 2.49-2.70).
Conclusion: Patients with outpatient random plasma glucose (RPG) ≥130 mg/dl have a higher risk of stress hyperglycemia, which is associated with longer length of stay, more acute kidney injury, and higher incidence of diabetes after discharge. Thus, patients with ≥2 pre-admission RPGs ≥130 should have inpatient RPGs monitored carefully, and those with high inpatient RPGs should be screened for diabetes for up to 3 years after discharge.
S. Fang: None. S. Aiyedipe: None. A. Khakharia: None. E. Giraldi: None. K. A. Easley: None. L. S. Phillips: Other Relationship; Self; Diasyst Inc., Research Support; Self; AbbVie Inc., Eli Lilly and Company, GlaxoSmithKline plc., Janssen Pharmaceuticals, Inc., Kowa Pharmaceuticals America, Inc., Novartis Pharmaceuticals Corporation, Novo Nordisk Pharma Ltd., Pfizer Inc., Sanofi-Aventis. M. K. Rhee: None.